Immunic's MS Drug Vidofludimus Shows Efficacy, Projected for $3-7B Peak Sales
IMUX has more than doubled off its 52-week low of $5.062.
Summary
Immunic announced positive efficacy and safety data for its oral drug vidofludimus calcium in treating relapsing and progressive multiple sclerosis. Crucially, the company projects peak sales for vidofludimus calcium to be between $3 billion and $7 billion. This highly material update on its lead drug candidate significantly overshadows the previously reported Q1 2026 financial results, which included a GAAP net loss of $32.59 million and an adjusted loss per share of $1.08. The substantial peak sales estimate, relative to Immunic's current market valuation, suggests significant upside potential. Traders will now closely monitor the anticipated Phase 3 data by the end of 2026 and the potential U.S. NDA filing for relapsing MS in mid-2027.
At the time of this announcement, IMUX was trading at $12.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176.4M. The 52-week trading range was $5.06 to $15.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.